RxDoctor Payments Data

Francis Crespo, MD

Interventional Cardiology · Miami, FLNPI 1528060555

Payments from drug & device makers

$12,159in general payments, 2019–2025

Across 234 payments — averaging $51.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Impulse Dynamics (USA) Inc.$1K
  • Biotronik Inc.$1K
  • Abbott$957
  • Boston Scientific$821
  • Johnson & Johnson$488
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$11,89398%
  • Education$2162%
  • Other$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,159 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$472,050
Medicare patients
140
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$115,504
EntrestoSacubitril/Valsartan101$100,353
XareltoRivaroxaban63$50,130
MounjaroTirzepatide17$19,362
OzempicSemaglutide14$13,726
VerquvoVericiguat16$12,306
FarxigaDapagliflozin Propanediol12$9,468
BrilintaTicagrelor17$7,489
Ranolazine ErRanolazine57$4,290
Nifedipine ErNifedipine81$1,926
Megestrol Acetate20$1,270
Rosuvastatin Calcium49$903
Labetalol Hcl77$785
Atorvastatin Calcium101$584
Hydralazine Hcl72$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$363$115,504159 claims
NovartisEntresto$394$100,353101 claims
Johnson & JohnsonXarelto$488$50,13063 claims
Lilly USA, LLCMounjaro$32$19,36217 claims
AstraZenecaFarxiga, Brilinta$217$16,95729 claims
Novo NordiskOzempic$21$13,72614 claims
MerckVerquvo$268$12,30616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →